Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study

Abstract

Background There have been reports of serious side effects of Remdesivir, including cardiovascular complications. The present study aimed to determine the adverse cardiovascular effects of Remdesivir and the factors affecting them in COVID-19 patients.

Methods The patients were classified into two groups: those receiving Remdesivir without cardiac complications and those receiving Remdesivir with cardiovascular complications. After reviewing the patientʼs medical records, the relationship of some factors with the incidence of adverse cardiovascular effects was measured.

Results Chi-square test showed that the distribution of complications in men was significantly higher than in women (P=0.001). The independent t-test revealed that the mean age in the group with complications was significantly higher than the group without complications (P=0.013). Fisherʼs exact test demonstrated a significant relationship between smoking and cardiovascular complications (P=0.05). According to the Mann-Whitney test, a significant difference was found in the mean changes of Bilirubin (P=0.02) and ALKP (P=0.01) before and after treatment in the groups with and without heart complications.

Conclusion Our findings indicated that most of the COVID-19 patients suffered from sinus bradycardia, and the distribution of complications was more pronounced in men than in women. The mean age in the group with complications was higher than the group without complications. Smoking was found to be associated with the occurrence of cardiovascular complications and the mean changes of Bilirubin and ALKP before and after treatment were significantly different in the groups with and without cardiovascular complications.

Keywords

remdesivir - cardiovascular system - side effects - COVID-19

Publication History

Received: 25 December 2023

Accepted: 22 May 2024

Article published online:
05 July 2024

• References

• 1 Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19. Pharmacotherapy. 2020; 40: 659-671
• 2 Amirian ES, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health 2020; 9: 100-128
• 3 Gordon CJ, Tchesnokov EP, Feng JY. et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020; 295: 4773-4779
• 4 Malin JJ, Suárez I, Priesner V. et al. Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev 2020; 34: e00162-20
• 5 Wang M, Cao R, Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-271
• 6 Pruijssers AJ, George AS, Schäfer A. et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep 2020; 32: 107940
• 7 Spinner CD, Gottlieb RL, Criner GJ. et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324: 1048-1057
• 8 Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 2020; 383: 1813-1826
• 9 Pan H, Peto R, Henao-Restrepo AM. et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384: 497-511
• 10 Goldman JD, Lye DCB, Hui DS. et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med 2020; 383: 1827-1837
• 11 Grein J, Ohmagari N, Shin D. et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020; 382: 2327-2336
• 12 Gottlieb RL, Vaca CE, Paredes R. et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med 2022; 386: 305-315
• 13 Hsu J. Covid-19: What now for remdesivir?. BMJ 2020; 371: m4457
• 14 Brunetti ND, Poliseno M, Bottalico IF. et al. Safety and heart rate changes in Covid-19 patients treated with Remdesivir. Int J Infect Dis 2021; 112: 254-257
• 15 Gupta AK, Parker BM, Priyadarshi V. et al. Cardiac adverse events with remdesivir in COVID-19 infection. Cureus 2020; 12: e11132
• 16 Mulangu S, Dodd LE, Davey RT. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293-2303
• 17 Nabati M, Parsaee H. Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review. Cardiovasc Toxicol 2022; 22: 268-272
• 18 Pallotto C, Suardi LR, Gabbuti A. et al. Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19). J Med Virol 2021; 93: 2631-2634
• 19 Gubitosa JC, Kakar P, Gerula C. et al. Marked sinus bradycardia associated with remdesivir in COVID-19: a case and literature review. JACC Case Rep 2020; 2: 2260-2264
• 20 Attena E, Albani S, Maraolo AE. et al. Remdesivir-induced bradycardia in COVID-19: a single center prospective study. Circ Arrhythm Electrophysiol 2021; 14: e009811
• 21 Touafchia A, Bagheri H, Carrié D. et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clin Microbiol Infect 2021; 27: 791.e5-8
• 22 Kanagala SG, Dholiya H, Jhajj P. et al. Remdesivir-Induced Bradycardia. South Med J 2023; 116: 317-320
• 23 Choi SW, Shin JS, Park SJ. et al. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Antiviral Res 2020; 184: 104955
• 24 Pelleg A, Belhassen B. The mechanism of the negative chronotropic and dromotropic actions of adenosine 5ʼ-triphosphate in the heart: an update. J Cardiovasc Pharmacol 2010; 56: 106-109
• 25 Onakpoya IJ. Rare adverse events in clinical trials: understanding the rule of three. BMJ Evid Based Med 2018; 23: 6
• 26 Rafaniello C, Ferrajolo C, Sullo MG. et al. Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System. Pharmaceuticals (Basel) 2021; 14: 611
• 27 Ogawa A, Ohira S, Kato Y. et al. Activation of the urotensin-II receptor by remdesivir induces cardiomyocyte dysfunction. Commun Biol 2023; 6: 511
• 28 Alsowaida YS, Shehadeh F, Kalligeros M. et al. Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study. Front Pharmacol 2023; 14: 1106044
• 29 Jung SY, Kim MS, Li H. et al. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clin Transl Sci 2022; 15: 501-513
• 30 Strait JB, Lakatta EG. Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail Clin 2012; 8: 143-164
• 31 Kim MM, Steffensen I, Miguel RTD. et al. Study title: A systematic review of RCTs to examine the risk of adverse cardiovascular events with nicotine use. Front Cardiovasc Med 2023; 10: 1111673
• 32 Haarhaus M, Brandenburg V, Kalantar-Zadeh K. et al. Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD. Nat Rev Nephrol 2017; 13: 429-442
• 33 Li J-W, Xu C, Fan Y. et al. Can serum levels of alkaline phosphatase and phosphate predict cardiovascular diseases and total mortality in individuals with preserved renal function? A systemic review and meta-analysis. PLoS One 2014; 9: e102276
• 34 Wu C, Song W, Xu Y. et al. The Nonlinear Relationship Between Total Bilirubin and Coronary Heart Disease: A Dose-Response Meta-Analysis. Front Cardiovasc Med 2021; 8: 761520
• 35 Horsfall LJ, Nazareth I, Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation. 2012; 126: 2556-2564
• 36 Arya S, Kumar P, Tiwari B. et al. What Every Intensivist should Know about Impairment of Cardiac Function and Arrhythmias in Liver Disease Patients: A Review. Indian J Crit Care Med 2020; 24: 1251-1255
• 37 Adamson C, Butt JH, Rouleau J. et al. Alkaline phosphatase and bilirubin combined are a powerful predictor of outcome in patients with heart failure and reduced ejection fraction: an analysis of the ATMOSPHERE and PARADIGM-HF trials. European Heart Journal 2022; 43: 544-871